Singer's groups performed digital PCR analysis of KRAS mutations in low-grade and high-grade ovarian serous carcinomas and found that KRAS activating mutations at codons 12 and 13 were prevalent in low-grade and borderline serous cancers, but were completely absent in their high-grade counterparts they examined[32]. The gene discussed is KRAS; the disease is ovarian serous carcinoma.